IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued on Thursday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Trading Up 2.6 %

Shares of NASDAQ:IRIX opened at $1.55 on Thursday. The company has a 50 day moving average of $1.67 and a 200-day moving average of $1.74. The firm has a market cap of $25.79 million, a P/E ratio of -2.31 and a beta of 0.84. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. The company had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period in the prior year, the company posted ($0.11) earnings per share.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.